Götz Thomalla,Florent Boutitie,Henry Ma,Masatoshi Koga,Peter Ringleb,Lee H Schwamm,Ona Wu,Martin Bendszus,Christopher F Bladin,Bruce C V Campbell,Bastian Cheng,Leonid Churilov,Martin Ebinger,Matthias Endres,Jochen B Fiebach,Mayumi Fukuda-Doi,Manabu Inoue,Timothy J Kleinig,Lawrence L Latour,Robin Lemmens,Christopher R Levi,Didier Leys,Kaori Miwa,Carlos A Molina,Keith W Muir,Norbert Nighoghossian,Mark W Parsons,Salvador Pedraza,Peter D Schellinger,Stefan Schwab,Claus Z Simonsen,Shlee S Song,Vincent Thijs,Danilo Toni,Chung Y Hsu,Nils Wahlgren,Haruko Yamamoto,Nawaf Yassi,Sohei Yoshimura,Steven Warach,Werner Hacke,Kazunori Toyoda,Geoffrey A Donnan,Stephen M Davis,Christian Gerloff,Evaluation of unknown Onset Stroke thrombolysis trials (EOS) investigators

Abstract:Background: Patients who have had a stroke with unknown time of onset have been previously excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe and effective in such patients when salvageable tissue has been identified with imaging biomarkers. Methods: We did a systematic review and meta-analysis of individual patient data for trials published before Sept 21, 2020. Randomised trials of intravenous alteplase versus standard of care or placebo in adults with stroke with unknown time of onset with perfusion-diffusion MRI, perfusion CT, or MRI with diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch were eligible. The primary outcome was favourable functional outcome (score of 0-1 on the modified Rankin Scale [mRS]) at 90 days indicating no disability using an unconditional mixed-effect logistic-regression model fitted to estimate the treatment effect. Secondary outcomes were mRS shift towards a better functional outcome and independent outcome (mRS 0-2) at 90 days. Safety outcomes included death, severe disability or death (mRS score 4-6), and symptomatic intracranial haemorrhage. This study is registered with PROSPERO, CRD42020166903. Findings: Of 249 identified abstracts, four trials met our eligibility criteria for inclusion: WAKE-UP, EXTEND, THAWS, and ECASS-4. The four trials provided individual patient data for 843 individuals, of whom 429 (51%) were assigned to alteplase and 414 (49%) to placebo or standard care. A favourable outcome occurred in 199 (47%) of 420 patients with alteplase and in 160 (39%) of 409 patients among controls (adjusted odds ratio [OR] 1·49 [95% CI 1·10-2·03]; p=0·011), with low heterogeneity across studies (I2=27%). Alteplase was associated with a significant shift towards better functional outcome (adjusted common OR 1·38 [95% CI 1·05-1·80]; p=0·019), and a higher odds of independent outcome (adjusted OR 1·50 [1·06-2·12]; p=0·022). In the alteplase group, 90 (21%) patients were severely disabled or died (mRS score 4-6), compared with 102 (25%) patients in the control group (adjusted OR 0·76 [0·52-1·11]; p=0·15). 27 (6%) patients died in the alteplase group and 14 (3%) patients died among controls (adjusted OR 2·06 [1·03-4·09]; p=0·040). The prevalence of symptomatic intracranial haemorrhage was higher in the alteplase group than among controls (11 [3%] vs two [<1%], adjusted OR 5·58 [1·22-25·50]; p=0·024). Interpretation: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care. A net benefit was observed for all functional outcomes despite an increased risk of symptomatic intracranial haemorrhage. Although there were more deaths with alteplase than placebo, there were fewer cases of severe disability or death. Funding: None.

Abstract 5: “Early Mobilization Protocol” Can Be Initiated In The Intensive Care Unit In Acute Ischemic Stroke Patients After Receiving Intravenous Alteplase

Minor Non-Disabling Stroke Patients with Large Vessel Severe Stenosis or Occlusion Might Benefit from Thrombolysis

Treatment with Intravenous Alteplase in Ischaemic Stroke Patients with Onset Time Between 4.5 and 24 Hours (HOPE): Protocol for a Randomised, Controlled, Multicentre Study.

Endovascular Thrombectomy with or Without Intravenous Alteplase in Acute Stroke

Abstract WP248: Pre-treatment Perfusion CT in Stroke Thrombolysis Can Predict Disability-free Life

Abstract WP33: Impact of Early Mobilization on Length of Stay in Acute Ischemic Stroke

Safety and Feasibility of Early Mobilization in Patients with Subarachnoid Hemorrhage and External Ventricular Drain

Abstract TP75: Waking Up To A New Wake-Up Stroke Protocol Is Feasible And Safe

Exploring the Unmet Need in Acute Ischemic Stroke Patients Not Treated With Intravenous Alteplase: The Get With The Guidelines‐Stroke Registry

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

Impact of Early Mobilization on Patients With Acute Ischemic Stroke Treated With Thrombolysis or Thrombectomy: A Randomized Controlled Trial

Application and effect evaluation of early rehabilitation for patients with acute cerebral infarction

Low-dose vs. standard-dose intravenous alteplase for acute ischemic stroke with unknown time of onset

Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials

Evaluation of Post-thrombolytic Events to Determine Appropriate ICU Monitoring Duration for Patients with Ischemic Stroke

Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients

Abstract WP146: Critical Care After Thrombolytic Therapy in Acute Stroke: Who Really Needs the ICU?

Optimization of Early Mobilization Program for Patients with Acute Ischemic Stroke: an Orthogonal Design

Abstract 1122‐000150: Novel Ischemic Stroke Treatment Protocol for Salvageable Penumbra in Acute Small Vessel Disease

Association of Intravenous Alteplase, Early Reperfusion, and Clinical Outcome in Patients With Large Vessel Occlusion Stroke: Post Hoc Analysis of the Randomized DIRECT-MT Trial

Abstract 76: Exploring Efficacy and Safety of Very Early Mobilization Within 24 Hours of Stroke Onset Versus Usual Stroke Unit Care (A Very Early Rehabilitation Trial, AVERT): Pre-specified Subgroup Analysis